Allworth Financial’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Allworth Financial’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-279	Closed	-$754	–	3450
2023 Q1	$754	Buy	279 +2	+0.7%	+$8	﹤0.01%	2763
2022 Q4	$1.1K	Hold	277	–	–	﹤0.01%	2440
2022 Q3	$2K	Hold	277	–	–	﹤0.01%	2280
2022 Q2	$3K	Hold	277	–	–	﹤0.01%	1964
2022 Q1	$5K	Hold	277	–	–	﹤0.01%	1654
2021 Q4	$18K	Hold	277	–	–	﹤0.01%	1173
2021 Q3	$19K	Hold	277	–	–	﹤0.01%	1066
2021 Q2	$19K	Hold	277	–	–	﹤0.01%	878
2021 Q1	$18K	Hold	277	–	–	﹤0.01%	829
2020 Q4	$16K	Buy	+277	New	+$16.1K	﹤0.01%	726

Allworth Financial's HTGM Position: Q2 2023 in Review

Allworth Financial sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 279 shares — an estimated $754 sold.

Allworth Financial first reported a position in HTGM in Q4 2020 and held it in 10 quarters. The position peaked at $19K in Q3 2021. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.

Allworth Financial reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Allworth Financial sold 279 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $754.
Allworth Financial first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Allworth Financial's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $19K in Q3 2021.
0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.

Based on Allworth Financial's 13F filing for Q2 2023, filed 18 Jul 2023.